

Novel Agents and Emerging Strategies in the Management of Gynecologic Cancers – Audio Program

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true about mirvetuximab soravtansine in the treatment of ovarian cancer?**
 - a. It is an antibody-drug conjugate that targets the folate receptor (FR) alpha
 - b. The associated ocular side effects are reversible
 - c. Both a and b**
 - d. Neither a nor b
- 2. Patients experiencing autoimmune thyroid toxicity while receiving anti-PD-1/ PD-L1 antibodies might present clinically with either hypothyroidism or hyperthyroidism.**
 - a. True**
 - b. False
- 3. Results from the Phase I GARNET study presented at ESMO 2018 included an overall response rate of approximately _____ with the anti-PD-1 antibody TSR-042 for patients with previously treated microsatellite instability (MSI)-high endometrial cancer.**
 - a. 10%
 - b. 50%**
 - c. 90%
- 4. Which of the following categories reflects the mechanism of action of tisotumab vedotin?**
 - a. Anti-PD-1 antibody
 - b. Anti-PD-L1 antibody
 - c. Antibody-drug conjugate targeted to tissue factor**
 - d. Anti-FR antagonist
- 5. The KEYNOTE-146 trial investigating the combination of pembrolizumab and lenvatinib for patients with previously treated, advanced endometrial cancer included patients with _____.**
 - a. MSI-high disease
 - b. Microsatellite stable disease
 - c. Both a and b**
 - d. Neither a nor b